Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts

One of the major sources of information on physiological and pathophysiological effects in pre-clinical oncology studies is the xenografted tumour animal model. However, measurement of tumour volume over time potentially masks a range of biological changes that the xenograft is undergoing. In this paper a mechanistic model of tumour growth in xenografts is presented that can be used to investigate the mode of drug action with respect to phenotypic changes. The model encapsulates key histological biomarkers and spatial constraints. The unknown model parameters are first shown to be uniquely identifiable from the proposed experimental studies, and then estimated from the resulting data using the anti-cancer agent docetaxel.

[1]  M. Sliwkowski,et al.  Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  J. Sharp,et al.  Blood volume determination in the mouse , 1973, The Journal of physiology.

[3]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[4]  Maria Pia Saccomani,et al.  Parameter identifiability of nonlinear systems: the role of initial conditions , 2003, Autom..

[5]  J. Beijnen,et al.  Preclinical pharmacokinetics of paclitaxel and docetaxel. , 1998, Anti-cancer drugs.

[6]  Eric Walter,et al.  Identifiability of parametric models , 1987 .

[7]  Neil D. Evans,et al.  Structural identifiability of surface binding reactions involving heterogeneous analyte: Application to surface plasmon resonance experiments , 2013, Autom..

[8]  Lennart Ljung,et al.  On global identifiability for arbitrary model parametrizations , 1994, Autom..

[9]  The Input-Output Relationship Approach to Structural Identifiability Analysis , 2010 .

[10]  Ghislaine Joly-Blanchard,et al.  Some effective approaches to check the identifiability of uncontrolled nonlinear systems , 2001 .

[11]  Daniel L. Gustafson,et al.  A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man , 2007, Clinical Cancer Research.

[12]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. McLeod,et al.  Evaluation of the linearity of docetaxel pharmacokinetics , 1998, Cancer Chemotherapy and Pharmacology.

[14]  K. Forsman.  Constructive Commutative Algebra in Nonlinear Control Theory , 1991 .

[15]  Benoît You,et al.  A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. , 2011, European journal of cancer.

[16]  R. Bellman,et al.  On structural identifiability , 1970 .

[17]  M. Bissery.  Preclinical pharmacology of docetaxel. , 1995, European journal of cancer.

[18]  H. Pohjanpalo.  System identifiability based on the power series expansion of the solution , 1978 .

[19]  J. DiStefano,et al.  Identifiability of Model Parameter , 1985 .

[20]  Elke S. Bergmann-Leitner,et al.  Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner] , 2005 .

[21]  P. Maini,et al.  A cellular automaton model for tumour growth in inhomogeneous environment. , 2003, Journal of theoretical biology.